The Cancer of the Pancreas Screening-5 CAPS5)Study

ConditionsPancreas Cancer Peutz-Jeghers Syndrome (PJS)Gene Mutation Germline Mutation Carrier Lynch Syndrome

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorJohns Hopkins University

About this trial

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Eligibility criteria

Qualifiers

Hereditary Pancreatitis or

Peutz-Jeghers Syndrome or

Strong family history of pancreas cancer on one side of the family tree or

Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR

Disqualifiers

Medical comorbidities or coagulopathy that contraindicate endoscopy

Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis

Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope

Poor performance status

Trial design

Treatments tested in this trial

Secretin
MRI
Tumor marker gene test with CA19-9

Treatment groups

9,000 Participants

are divided into 9 treatment groups

Treatment groups

See each treatment group below.

Sponsors and collaborators

Johns Hopkins University

Lead sponsor

National Cancer Institute (NCI)

Collaborator

National Institutes of Health (NIH)

Collaborator

American Association for Cancer Research

Collaborator

Source ClinicalTrials.gov